ENDOMETRIAL CANCER

This study tested a new radioactive drug, [225Ac]-FPI-1434, in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited. It involved 78 partic…

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced endometrial or ovarian cancers that are hormone receptor-positive and have certain gene changes (PI3K/PTEN). The goal was to see if the combination was safe and effective. Only 7 peo…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had stopped responding …

This early-stage study tested an experimental drug called BLU-222 in 50 people with advanced solid tumors (like breast, ovarian, or stomach cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The st…

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific PALB2 gene mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stopped early, so results are …

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women whose endometrial cancer had come back. Only 4 people took part before the study was stopped early. The treatment requires ongoing medication and is not a cure.

This early-phase study tested a new drug called PHN-010 in 26 people with advanced solid tumors (lung, colon, endometrial, ovarian, or cervical cancer) that had already been treated with at least one prior therapy. The drug is an antibody-drug conjugate designed to deliver a toxi…

This early-stage study tested an experimental oral drug called ATX-559 in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and understand side effects. The study was terminated early, so results are lim…

This study looked at whether taking the hormone therapy letrozole after standard treatment could help prevent endometrial cancer from coming back in patients with a non-specific molecular profile. The trial planned to include 12 participants but was terminated early, so results a…

This study looked at 92 women with high-risk endometrial cancer who needed pelvic radiation after surgery. It compared a newer, more precise radiation method (IMRT) with the standard 3D technique to see if it could reduce side effects like bowel and bladder problems. The goal was…